Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gynecologic 1Dermatologic 1Breast 1

Conditions

Diarrhea 2Breast Neoplasms 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urogenital Neoplasms 1Rectal Neoplasms 1Ovarian Neoplasms 1Melanoma 1Lung Neoplasms 1Low Anterior Resection Syndrome 1Colitis 1

Interventions

pembrolizumab 49Carboplatin 44Magnetic Resonance Spectroscopy 40Specimen Handling 39Pemetrexed 35Cisplatin 26Blood Specimen Collection 25durvalumab 17Paclitaxel 17osimertinib 15Radiosurgery 15Bevacizumab 15Radiotherapy 14Nivolumab 14Gemcitabine 14atezolizumab 13Biopsy 13Drug Therapy 12Docetaxel 11130-nm albumin-bound paclitaxel 11Immunoglobulin G 10X-Rays 9Taxes 9Standard of Care 9Practice Guidelines as Topic 9Educational Status 9Disulfides 9tislelizumab 8Etoposide 8Cetuximab 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Lung Neoplasms × Loperamide × Clear all
NCT04038619 2026-03-20

Fecal Microbiota Transplantation in Treating Immune-Checkpoint Inhibitor Induced-Diarrhea or Colitis in Genitourinary Cancer Patients

M.D. Anderson Cancer Center

Phase 1 Recruiting
40 enrolled
BreastDermatologicGynecologicThoracic

Breast Neoplasms, Uterine Cervical Neoplasms, Colitis, Diarrhea, Lung Neoplasms, Melanoma, Ovarian Neoplasms, Urogenital Neoplasms, Uterine Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡